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To investigate the prevalence of and the risk factors for cervical infection with human papillomavirus (HPV) in an inner-city area of
Ibadan, Nigeria, we interviewed and obtained a sample of cervical cells from 932 sexually active women aged 15 years or older. A
total of 32 different HPV types were identified with an HPV prevalence of 26.3% overall and 24.8% among women without cervical
lesions; or age-standardised to the world standard population of 28.3 and 27.3%, respectively. High-risk HPV types predominated,
most notably HPV 16, 31, 35 and 58. In all, 33.5% of infections involved more than one HPV type. Unlike most populations studied so
far, HPV prevalence was high not only among young women, but also in middle and old age. Single women (odds ratio, OR¼2.1;
95% confidence interval, CI¼1.1–3.9) and illiterate women (OR¼1.7; 95%CI¼1.1–2.5) showed increased HPV positivity.
Associations were also found with anti-Herpes simplex-2 antibodies (OR¼1.6; 95% CI: 1.1–2.1) and with the husband’s extramarital
relationships (OR¼1.6: 95% CI: 1.0–2.6). High prevalence of HPV in all age groups may be a distinctive feature of populations where
HPV transmission continues into middle age and cervical cancer incidence is very high.
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The prevalence of cervical infection with human papillomavirus
(HPV), particularly of high-risk (HR) types that cause cervical
cancer (Mun ˜oz et al, 2003), varies greatly worldwide. A series of
population-based HPV surveys coordinated by the International
Agency for Research on Cancer (IARC) has shown a 10-fold
variation between some areas in Spain (de Sanjose ´ et al, 2003) and
North Vietnam (Anh et al, 2003), where HPV prevalence in
sexually active women aged 15–65 years was below 2%, and areas
in Colombia (Molano et al, 2002) and Argentina (Matos et al,
2003), where it was 15% or greater. The prevalence of HR HPV
types in middle-aged women and the incidence of cervical cancer
in the same age group were strongly positively correlated
(Franceschi et al, 2003a).
The incidence of cervical cancer in sub-Saharan Africa is among
the highest worldwide, with age-standardised rates of 35.7 per
100000 in Bamako, Mali, and 41.7 per 100000 in Kyadondo,
Uganda (Parkin et al, 2002), yet only recently has information on
the prevalence of cervical HPV infection become available
(Serwadda et al, 1999; Castellsague et al, 2001; Gravitt et al,
2002; De Vuyst et al, 2003; Xi et al, 2003).
Nigeria is the most populous country in Sub-Saharan Africa,
with approximately 117 million inhabitants, a life expectancy at
birth of 50.6 years in men and 52.6 years in women, child mortality
of 159 and 152 per 1000 in males and females, respectively, and per
capita total expenditure on health of US$8 per year (http://
www.who.int). The annual age-standardised incidence of cervical
cancer in Ibadan in 1998–1999 was 19.9 per 100000 (Parkin et al,
2003).
Here, we report the first study from Nigeria of the prevalence of
cervical HPV infection.
MATERIALS AND METHODS
Study subjects
A survey was carried out in April and May 1999 enumerating the
female population of the Idikan community, an inner-city, densely
populated area of Ibadan north west local government area,
consisting mainly of Muslim people of low socioeconomic level. A
total of 2870 women aged 15 years or older were estimated to live
in Idikan. After meetings with community representatives, women
were contacted up to three times at their home by four female
nurses and asked to come to the Idikan Clinic that is run by the
Preventive and Social Medicine Department of the University of
Ibadan. According to the exclusion criteria of the protocol of IARC
HPV surveys, women who: (1) were pregnant; (2) had undergone
hysterectomy or conisation; and (3) were physically or mentally
unable to undergo an interview and a pelvic examination were not
invited to participate in the present study.
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who had been enumerated) came to the Idikan Clinic for an
interview and a pelvic examination. Participation was higher
among women aged 30 years or older (66.1%) than among younger
women (31.9%) on account of the exclusion of pregnant women
and low compliance of nonsexually active women. We therefore
excluded from the present report 62 self-reported virgins.
Furthermore, 14 women who had moved away from Idikan, 36
who refused a pelvic examination, and, despite exclusion criteria,
47 women who were pregnant, six who had been hysterectomised,
and 22 women who were physically unable to undergo pelvic
examination were also excluded.
The interview was administered in the local language (Yoruba)
by four research nurses. The structured questionnaire, similar to
the other HPV survey coordinated by IARC (Shin et al, 2003),
included information on sociodemographic characteristics, smok-
ing and chewing habits, reproductive and menstrual factors, sexual
habits of the woman and her husband, and lifetime use of
contraceptive methods.
All participants signed informed consent forms according to the
recommendations of the IARC and local ethical review committees
that had approved the study. When indicated, participating women
were treated for minor ailments and given multivitamin supple-
ments.
Gynaecological examination and specimen collection
A total of 1203 sexually active women underwent a pelvic
examination by one of the four female nurses. In order to evaluate
the feasibility and validity of different screening methods in
Nigeria, two different types of tests were performed: Papanicolau
(Pap) smear and visual inspection with acetic acid (VIA). In
addition, samples of exfoliated cells from the ectocervix and from
the endocervix were collected with two Ayre spatulae and a
cytobrush (Cervibrush, CellPath). After the preparation of a Pap
smear, the remaining exfoliated cervical cells were placed in 50ml
conic tubes that contained 20ml of phosphate-buffered saline
(PBS). All samples were stored in iceboxes and sent daily to the
laboratory of the Pathology Department of the University College
Hospital, Ibadan, for processing and storage. Samples of exfoliated
cells were centrifuged at 3000g and the resulting pellet was diluted
in 1ml of PBS and poured into labelled tubes. All samples were
stored at  201C until shipment on dry ice to IARC.
After taking the smear, 4% freshly prepared acetic acid was
generously applied on the cervix using soaked cotton wool swabs
and a minute after the cervix was examined to evaluate the
presence of: (a) faint acetowhite areas; or (b) dense acetowhite
areas (Sankaranarayanan et al, 1998).
Participants with abnormal findings at cytological or VIA
examination were referred, free of charge, to the Gynaecology
Department of the University College Hospital, Ibadan, for
colposcopic examination and, if appropriate, biopsy and treat-
ment.
Pap smears were read at the Pathology Department of the
University College Hospital, Ibadan, and classified according to the
Bethesda system. Pap smear results were used preferentially for
study purposes and were available for 1110 women. For 93
additional women, however, a Pap smear was lost (two) or was
inadequate (91 women). We, therefore, classified them as
abnormal if the VIA had revealed white lesions. Finally, women
were also asked to provide 10ml of blood.
Human papillomavirus and Herpes simplex-2 (HSV-2)
detection techniques
Human papillomavirus DNA test Human papillomavirus testing
was performed on exfoliated cervical cells from 1177 sexually
active women. To analyse the quality of target DNA for polymerase
chain reaction (PCR) testing, cervical specimens were screened
with b-globin gene-specific primers. In total, 245 samples were
found to be b-globin negative and, as a result, valid HPV results
were available for 932 women.
Human papillomavirus positivity was assessed by general
primer-mediated GP5þ/6þ-PCR and by hybridisation of PCR
products in an enzyme immunoassay (EIA) using two HPV
oligoprobe cocktails that together detect the following 36 HPV
types: HPV 6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51,
52, 53, 54, 55, 56, 57, 58, 59, 61, 66, 68, 70, 71 (equivalent to
CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4
subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), and
CP 6108. Polymerase chain reaction products that were positive in
the EIA were subsequently subjected to further typing by reverse
line blot hybridization (RLB). Probes and procedures used for EIA
and RLB are described elsewhere (van den Brule et al, 2002). In
addition, EIA-negative samples were tested by low-stringency
Southern blot analysis of PCR products with a cocktail probe of
HPV-specific DNA fragments to assess whether HPV types were
present that were not represented in EIA oligoprobe cocktails.
None of such types was found. Special precautions were taken to
minimise false-positive results in the PCR, as has been described
elsewhere (Walboomers et al, 1999).
HR HPV types for this analysis included HPV types 16, 18, 26,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 (Mun ˜oz
et al, 2003). The group of low-risk (LR) types included all other
HPV types. Human papillomavirus infections having more than
one HPV type (i.e., multiple HPV infections) were considered as
HR if any of the types detected was an HR type.
Herpes simplex-2 plasma antibodies The presence of type-specific
plasma IgG antibodies against HSV-2 (anti-HSV-2) was tested
using an HSV-2 ELISA assay developed by Focus Technology/
formerly MRL (Cypress, California) (Ribes et al, 2001). All HSV-2
positive findings were confirmed by means of a second test. Valid
HSV-2 results were available from 892 women with valid HPV
findings.
Statistical analysis
Odds ratios (ORs) for HPV positivity and corresponding 95%
confidence intervals (CIs) were calculated by means of uncondi-
tional, multiple logistic regression equations, adjusted for age
(o25; 25–34; 35–44; 45–54; 55–64; X65 years). Variables that
showed statistically significant associations with HPV positivity in
the age-adjusted analyses were included in the same model and
evaluated overall and in separated strata by age group, HR and LR
HPV types, and multiplicity of infections. The statistical sig-
nificance of trends for ORs was assessed by considering the
categorical variable as a continuous variable in the logistic model.
RESULTS
Among the 932 women who had a cytological or VIA examination
and valid HPV results, 844 (90.6%) had normal cervical findings.
Among the 862 women for whom a Pap smear was available, 19
(2.2%) showed atypical squamous cells of undetermined signifi-
cance (ASCUS), one showed atypical glandular cells of undeter-
mined significance (AGUS), 37 (4.3%) low-grade intraepithelial
lesions, and 15 (1.7%) high-grade intraepithelial lesions. In
addition, one in situ and one invasive cervical cancer were
detected. Among 70 women who were screened only by means of
VIA, 12 (17.1%) had faint white lesions and two (2.8%) had dense
white lesions. Only nine women reported to have ever had a Pap
smear before.
The prevalence of HPV of any type was 26.3, 24.8 and 40.9%,
respectively, among women with normal and abnormal cervical
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dardised to the world population was 28.3% overall, and 27.3%
among women without cervical lesions. A total of 82 (8.8% overall,
33.5% of HPV-positive women) had multiple HPV infections and a
total of 385 HPV infections with 32 different HPV types were
detected. High-risk HPV infections were substantially more
frequent (19.7% of all women) than LR HPV infections (6.6%).
The most commonly found HPV types, in either single or multiple
infections, were HPV 42 (an LR type, 41 women), HPV 16 (30
women), and HPV 35 (30 women), but the type distribution varied
by cervical findings. Human papillomavirus 42 was never found in
single infections in women with cervical abnormalities. An HR
HPV type was found in 34.1% of women with abnormal cervical
findings, and in 18.3% of those with normal cervical findings. All
three women in whom biopsy showed a cervical intraepithelial
lesion grade 3 and two women with in situ or invasive cervical
carcinomas were HR HPV positive. Combinations of HPV types
found in women with multiple HPV infections are given in the
appendix.
Figure 1 shows the age pattern of the prevalence of HPV (any
type and HR and LR types separately) and that of anti-HSV-2.
Anti-HSV-2 was approximately twice as frequent as HPV positivity
in any given age group.
Tables 2–4 show the relationship between the HPV positivity
and age and the major characteristics of the study women after
adjustment for age. Human papillomavirus prevalence was not
significantly different in the age groups considered, ranging
between 30.8% among women younger than 25 years and 24.4%
among those in the 55–64 age range (Table 2). Illiteracy, which
was reported by 45.7% of women, was associated with an OR for
HPV-positivity of 1.7 (95% CI: 1.1–2.5). Only 1.8% of the study
women had ever smoked cigarettes (OR¼1.6; 95% CI: 0.6–4.5,
data not shown), but 35.6% reported a chewing habit (OR¼1.4;
95% CI: 1.0–1.9). In all, 96% of chewers chewed kola-nut, while 12
(3.6%) chewed a mixture of products that, in three women,
included tobacco.
Single women, who accounted for 6.7% of our study partici-
pants, showed an OR of 2.1 (95% CI: 1.1–3.9), whereas no excess
Table 1 Prevalence of 32 HPV types by findings at cytological smear or VIA and overall among 932 women, Ibadan, Nigeria
Cytology/VIA
Normal Abnormal Total
HPV type Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
HPV  635 (75.2) 52 (59.1) 687 (73.7)
HPV+ 141 68 209 (24.8) 22 14 36 (40.9) 163 82 245 (26.3)
HR HPV+ 93 61 154 (18.3) 17 13 30 (34.1) 110 74 184 (19.7)
LR HPV+ 48 7 55 (6.5) 5 1 6 (6.8) 53 8 61 (6.6)
High-risk infections
16 14 11 25 (3.0) 2 3 5 (5.7) 16 14 30 (3.2)
18 6 8 14 (1.7) 1
a 3
b 4 (4.6) 7 11 18 (1.9)
26 0 2 2 (0.2) 1 0 1 (1.1) 1 2 3 (0.3)
31 6 16 22 (2.6) 4
a 1 5 (5.7) 10 17 27 (2.9)
33 1 4 5 (0.6) 0 0 0 1 4 5 (0.5)
35 12 13 25 (3.0) 1 4 5 (5.7) 13 17 30 (3.2)
39 2 3 5 (0.4) 0 1 1 (1.1) 2 4 6 (0.6)
45 9 9 18 (2.1) 1 0 1 (1.1) 10 9 19 (2.0)
51 6 3 9 (1.1) 1 4 5 (5.7) 7 7 14 (1.5)
52 3 10 13 (1.5) 2 2 4 (4.6) 5 12 17 (1.8)
53 1 1 2 (0.2) 0 0 0 1 1 2 (0.2)
56 6 12 18 (2.1) 2
a 2 4 (4.6) 8 14 22 (2.4)
58 10 11 21 (2.5) 1 1 2 (2.3) 11 12 23 (2.5)
59 3 2 5 (0.6) 0 0 0 3 2 5 (0.5)
66 12 5 17 (2.0) 0 3 3 (3.4) 12 8 20 (2.2)
68 0 2 2 (0.2) 0 0 0 0 2 2 (0.2)
73 0 4 4 (0.5) 0 0 0 0 4 4 (0.4)
82 2 1 3 (0.4) 1
c 0 1 (1.1) 3 1 4 (0.4)
Subtotal 93 117 210 (—) 17 24 41 (—) 110 141 251 (—)
Low-risk infections
6 2 1 3 (0.4) 0 5 5 (5.7) 2 6 8 (0.9)
11 0 3 3 (0.4) 0 1 1 (1.1) 0 4 4 (0.4)
34 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
40 3 5 8 (1.0) 1 0 1 (1.1) 4 5 9 (1.0)
42 20 17 37 (4.4) 0 4 4 (4.6) 20 21 41 (4.4)
43 1 3 4 (0.5) 0 1 1 (1.1) 1 4 5 (0.5)
54 0 2 2 (0.2) 0 0 0 0 2 2 (0.2)
55 0 3 3 (0.4) 0 0 0 0 3 3 (0.3)
70 3 5 8 (1.0) 1 0 1 (1.1) 4 5 9 (1.0)
72 4 6 10 (1.2) 2 0 2 (2.3) 6 6 12 (1.3)
81 9 14 23 (2.7) 1 2 3 (3.4) 10 16 26 (2.8)
83 4 5 9 (1.1) 0 2 2 (2.3) 4 7 11 (1.2)
84 2 0 2 (0.2) 0 0 0 2 0 2 (0.2)
CP6108 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
Subtotal 48 66 114 (—) 5 15 20 (—) 53 81 134 (—)
Total 141 183 324 (—) 22 39 61 (—) 163 222 385 (—)
HPV¼human papillomavirus; VIA¼visual inspection with acetic acid.
aIt includes one histologically confirmed cervical intraepithelial neoplasm 3.
bIt includes one in situ squamous
cell carcinoma of the cervix.
cIt includes one invasive squamous cell carcinoma of the cervix.
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women compared to currently married ones. Only 6.3% of women
had never been pregnant, whereas 61.0% reported five pregnancies
or more. Nulligravidae showed, vs women with one or two
pregnancies, an OR of 1.7 (95% CI: 0.8–3.4), but the trend in risk
by number of pregnancies was not significant. In all, 15.1% of
women reported becoming pregnant for the first time before the
age 20 years but age at first pregnancy was not significantly
associated with HPV positivity (Table 2). Odds ratios for different
number of births were very similar to those for number of
pregnancies. The OR for HPV positivity among 356 (38.2%)
women who reported one abortion or more (mainly miscarriages)
was 0.9 (95% CI: 0.7–1.2) (data not shown).
Among indicators of sexual habits (Table 3), age at first
intercourse (below 20 years of age in 49.3% of study women)
seemed unrelated to HPV prevalence. Two lifetime sexual partners
or more were reported by 47.1% of the study women and a direct
association of borderline statistical significance was found with
HPV positivity (OR for three partners or more vs one¼1.4, 95%
CI: 0.9–2.0). Regular sexual partners (i.e., male sexual partners in
relationships that had lasted at least 6 months) and occasional
sexual partners were also evaluated separately (data not shown).
The OR for two regular sexual partners or more was 1.2 (95% CI:
0.9–1.7). A history of occasional sexual partners (19.1% of study
women) was associated with an OR of 1.3 (95% CI: 0.9–1.8). Only
15.6% of study women believed that that their husbands had not
had extramarital sexual relationships. The OR for HPV positivity
among those women who were certain about their husbands
having had an extramarital sexual relationship was 1.6 (95% CI:
1.0–2.6). According to the women, such relationships involved
sex-workers only in a minority of cases. The presence of anti-HSV-
2 (61.3% of women) was associated with an OR of 1.6 (95% CI:
1.1–2.1). Use of hormonal contraceptives (including 41 women
who had used injectable types) and condom was reported by 13.6
and 9.0% of the study women, respectively, and was unrelated to
HPV prevalence. Intrauterine devices were used more frequently
than any other contraceptive methods and showed an OR of 1.3, of
borderline statistical significance (Table 3).
The effect of age group and significant risk factors for HPV
positivity in age-adjusted analyses is reassessed in Table 4 by
means of multiple logistic regression using all listed variables,
overall and separately, in women below and above age 35 years, in
HR and LR HPV infections and in single and multiple infections.
No significant heterogeneity emerged between the different strata.
Among all women, only illiteracy and the presence of anti-HSV-2
retained a significant association in the multivariate analyses. The
age pattern of HPV positivity was substantially changed in the
multivariate analysis, suggesting that high HPV positivity in older
women was accounted for by a greater prevalence of some
unfavourable characteristics, chiefly illiteracy, which increased
from 5.9% in women below age 25 years to 87.9% in those aged 55
years or older.
DISCUSSION
The prevalence of HPV positivity of 26.3% found in Ibadan,
Nigeria is consistent with previous reports of the elevated
prevalence of HPV in women in Sub-Saharan Africa. The age
pattern was notable, however, with a modest peak of HPV
infections (mainly HR HPV types) among women younger than
25 years and a consistently high prevalence among middle-aged
and old women. The prevalence of anti-HSV-2 was also high
(61.3%), reaching maximal levels already in women below age of
25 years. Being single and illiterate were the main correlates of
HPV positivity among study women.
Previous HPV surveys in sub-Saharan Africa have generally
shown relatively high HPV prevalence with some variation,
Table 2 Odds ratios (ORs) for HPV positivity and corresponding 95%
confidence intervals (CIs) according to sociodemographic and reproductive
characteristics among 932
a women, Ibadan, Nigeria
HPV positive
Number of women N (%) OR
b 95% CI
Age (years)
o25 120 37 (30.8) 1
25–34 189 48 (25.4) 0.8 (0.5–1.3)
35–44 134 36 (26.9) 0.8 (0.5–1.4)
45–54 196 51 (26.0) 0.8 (0.5–1.3)
55–64 172 42 (24.4) 0.7 (0.4–1.2)
X65 121 31 (25.6) 0.8 (0.4–1.4)
w
2
1 for trend 0.74; P¼0.39
Education
Primary or better 495 121 (24.4) 1
Illiterate 417 117 (28.1) 1.7 (1.1–2.5)
Chewing habit
No 600 147 (24.5) 1
Yes 331 98 (29.6) 1.4 (1.0–1.9)
Marital status
Married 687 178 (25.9) 1
Single 62 25 (40.3) 2.1 (1.1–3.9)
Divorced/widowed 183 42 (23.0) 0.8 (0.5–1.3)
Number of pregnancies
0 57 22 (38.6) 1.7 (0.8–3.4)
1–2 134 39 (29.1) 1
3–4 164 45 (27.4) 0.8 (0.5–1.4)
5–6 230 49 (21.3) 0.6 (0.3–1.0)
X7 326 87 (26.7) 0.7 (0.4–1.3)
w
2
1 for trend 1.96; P¼0.16
Age at first pregnancy (years)
X25 253 69 (27.3) 1
20–24 479 115 (24.0) 0.8 (0.6–1.2)
p19 132 38 (28.8) 1.0 (0.6–1.7)
w
2
1 for trend 0.02 P¼0.90
HPV¼human papillomavirus.
aSome figures do not add up to the total because a few
are missing.
bAdjusted for age.
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Figure 1 Age-specific prevalence of HPV and anti-HSV-2 antibodies.
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for. Using the hybrid capture (HC) assay II, a 17% prevalence of
HR HPV types was found in rural Uganda (Serwadda et al, 1999),
while a 25% prevalence was found among HIV-negative women in
Harare, Zimbabwe (Womack et al, 2000). Polymerase chain
reaction-based assays showed HPV prevalence of 40% in rural
Mozambique (Castellsague et al, 2001), of 31% in Harare,
Zimbabwe (Gravitt et al, 2002), of 18% in Dakar and Pikene,
Senegal (Xi et al, 2003), and of 44% in Nairobi, Kenya (De Vuyst
et al, 2003). As in most previous studies (Castellsague et al, 2001;
Gravitt et al, 2002; De Vuyst et al, 2003), we found that multiple
HPV infections were involved in a substantial fraction of HPV-
positive women.
Several authors have raised the possibility of certain HPV types
being more common in Sub-Saharan African women than
elsewhere. HPV 35, for instance, was slightly more common than
HPV 16 in Mozambique both in women with normal cytology and
in those with HSIL or worse (Castellsague et al, 2001). HPV 52 was
found slightly more frequently than HPV 16 or HPV 35 in Kenya
(De Vuyst et al, 2003) and in colposcopically normal women in
Zimbabwe (Gravitt et al, 2002). In Senegal, HPV 16 and 58 were the
most common types overall and in women with cervical lesions (Xi
et al, 2003). In our study, when the frequency of HPV types both in
single and multiple infections were combined, HPV 16 and 35 were
the most common HR types, followed by HPV 31, 58, and 56. An
LR type, HPV 42, was also common.
Several caveats are relevant to the interpretation of variations in
HPV type distribution. As noted by Gravitt et al (2002), type-
specific HPV prevalence may be influenced by the type of assay
used and by the high proportion of multiple HPV infection in
certain populations. Furthermore, studies from sub-Saharan Africa
have shown variations in the relative ranking of HPV types that are
compatible with chance and everywhere the predominance of HPV
16 and 18 rises with the increasing severity of cervical findings
(Clifford et al, 2003a,b). The type-specific distribution of HPV
among 799 cervical cancer biopsies from Africa showed that HPV
16 accounted for 50.2% of samples, HPV 18 for 14.1%, and HPV 45
for 7.9% (i.e., a distribution similar to that found worldwide)
(Clifford et al, 2003b).
The age pattern of HPV prevalence also differs somewhat from
one country to another. The predominant pattern includes an early
peak, soon after the start of sexual intercourse (Jacobs et al, 2000;
Kjaer et al, 2001), followed by lower levels of HPV positivity in
middle age (Jacobs et al, 2000; Sellors et al, 2000; Molano et al,
2002; Anh et al, 2003; de Sanjose ´ et al, 2003; Matos et al, 2003; Shin
et al, 2003; Sukvirach et al, 2003). U-shaped curves were also
found, but the age group with the lowest HPV prevalence was not
entirely consistent (e.g., at ages 35–54 years in Costa Rica,
(Herrero et al, 2000) and 35–44 years in Mexico (Lazcano-Ponce
et al, 2001)). In three studies from sub-Saharan Africa (Serwadda
et al, 1999; Castellsague et al, 2001; De Vuyst et al, 2003), the
prevalence of HPV declined with age. In one study (Xi et al, 2003)
Table 3 Odds ratios (OR) for HPV positivity and corresponding 95% confidence intervals (CIs) according to indicators of sexual habits and use of
contraceptive methods among 932 women,
a Ibadan, Nigeria
HPV positive
Number of women N (%) OR
b 95% CI
Age at first intercourse (years)
p20 472 122 (25.8) 1
18–19 228 60 (26.3) 0.98 (0.7–1.4)
p17 231 63 (27.3) 0.99 (0.7–1.5)
w
2
1 for trend 0.01; P¼0.94
Lifetime sexual partners
1 491 118 (24.0) 1
2 267 76 (28.5) 1.3 (0.9–1.8)
X3 170 51 (30.0) 1.4 (0.9–2.0)
w
2
1 for trend 3.2; P¼0.07
Husband’s extramarital sexual relationships
No 145 30 (20.7) 1
Unknown 162 41 (25.3) 1.3 (0.8–2.3)
Yes 625 174 (27.8) 1.6 (1.03–2.6)
Anti-herpes simplex 2 antibodies
No 345 74 (21.4) 1
Yes 547 163 (29.8) 1.6 (1.1–2.1)
Use of hormonal contraceptives
Never 805 215 (26.7) 1
Ever 127 30 (23.6) 0.9 (0.5–1.3)
Use of condoms
Never 848 225 (26.5) 1
Ever 84 20 (23.8) 0.8 (0.5–1.4)
Use of intrauterine device
Never 776 199 (25.6) 1
Ever 156 46 (29.5) 1.3 (0.9–1.9)
HPV¼human papillomavirus.
aSome figures do not add up to the total because a few are missing.
bAdjusted for age.
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than younger women.
The high prevalence of HPV in middle and old age in Ibadan,
Nigeria may have different explanations. A fraction of men and
women in Ibadan may continue to have multiple sexual contacts
throughout their life and therefore reinfect themselves and their
spouses. Women in Ibadan may also have decreased ability to clear
HPV infections, possibly due to concomitant genital infections or
nutritional deficiencies. We found an age pattern similar to the one
in Ibadan in another population at very high-risk for cervical
cancer, namely, Chennai, Southern India (Franceschi et al, 2003b).
Most of the risk factors for HPV positivity we had identified,
notably illiteracy (as an indicator of poverty), chewing, and
husbands’ extramarital relationships, were more frequent among
older than young women.
It is noteworthy that the presence of anti-HSV-2, multiplicity of
sexual partners, and husbands’ extramarital sexual relationships
were common in Ibadan but that the association of these factors
with HPV positivity was relatively weak. As noted with respect to
male sexual habits in another high-risk area (Colombia) (Mun ˜oz
et al, 1996), the effect of variations in individual sexual habits
becomes difficult to detect in populations where the background
prevalence of sexually transmitted disease exceeds a certain
threshold. The number of pregnancies was not significantly
associated with HPV positivity. The higher proportion of HPV-
positive women among nulligravidae was chiefly due to the fact
that 80.7% of them were single (OR for nulligravidae vs gravidae,
adjusted for marital status¼1.0; 95% CI: 0.4–2.7). Finally, the
habit of chewing was another correlate of HPV positivity in our
study. We have previously reported an association between
chewing habit and cervical cancer in Southern India, where paan
is chiefly composed of betel leaves, areca nut, and tobacco
(Rajkumar et al, 2003). In Nigeria, women reported chewing kola-
nut almost exclusively (Cola nitida and Cola acuminata), which is
high in caffeine, and serves as a stimulant (Morton 1992).
The potential limitations of our survey include the relatively
high proportion of inadequate cervical cell samples and the low
participation rate. The relatively high proportion of b-globin
negativity in the cervical cell samples may be due to problems in
the transport or storage of cervical cell samples or to the limited
experience of our study nurses in cervical cell collection. High
proportions of b-globin negative samples have been a problem in
other IARC surveys in developing countries (Anh et al, 2003;
Sukvirach et al, 2003). Cytological findings were missing or
inadequate in approximately 10% of women and were substituted,
in order to stratify HPV prevalence by the presence of cervical
abnormalities, by VIA findings. Reliance on VIA, which is
known to be less specific than Pap smear (Sankaranarayanan
et al, 1998), was, however, necessary in fewer than 100 women.
Their exclusion would have not altered our findings on HPV
prevalence by the presence of cervical lesions. Problems with
the preparation, and the classification of Pap smears may explain
the relatively low proportion of HPV positivity among women with
cervical abnormalities but would not affect our conclusions
overall.
With respect to the 390 eligible women who were interviewed
but for whom information on HPV or cervical status could not be
obtained on account of various technical problems, their distribu-
tion by sexual and nonsexual factors was similar to that of women
who were included in our final analyses, thus weighing against a
clear selection bias. It is also reassuring that the distribution of
some of the characteristics investigated (e.g., multiple sexual
partners, parity, use of OCs or condoms) was consistent with those
reported nationwide by publications of the World Health
Organization (http://www.who.int).
Finally, we did not have information on HIV status. The
most recent findings from HIV Surveillance in Ibadan showed
an HIV prevalence of 3.3% among pregnant women in 2001,
22.6% among female sex workers in 1995, and 6.2% among
patients of sexually transmitted disease clinics in 1993 (http://
www.unaids.org). Peak infection occurred among women
less than 30 years and would, therefore, not explain the
high HPV prevalence we found among women of middle and old
age.
Table 4 Odds ratios (ORs)
a and corresponding 95% confidence intervals (CIs) for major risk factors for HPV positivity by age group, HPV type, and
multiplicity of infection and overall among 932 women, Ibadan, Nigeria
Age HPV type(s) Multiplicity
o35 X35 Low-risk High-risk Single Multiple Total
Age (years)
o2 5 1 — 1111 1
25–34 0.8 (0.4–1.3) — 1.7 (0.7–4.6) 0.6 (0.3–1.01) 1.0 (0.6–1.2) 0.4 (0.2–0.9) 0.8 (0.5–1.3)
35–44 — 1 0.9 (0.3–2.7) 0.6 (0.3–1.1) 0.8 (0.4–1.5) 0.5 (0.2–1.2) 0.6 (0.4–1.1)
45–54 — 1.6 (0.8–2.9) 0.7 (0.2–2.2) 0.5 (0.3–0.9) 0.6 (0.3–1.1) 0.4 (0.2–1.1) 0.5 (0.3–0.9)
55–64 — 1.3 (0.7–2.2) 0.3 (0.1–1.2) 0.5 (0.2–0.9) 0.4 (0.2–0.8) 0.5 (0.2–1.3) 0.4 (0.2–0.8)
X65 — 1.0 (0.6–1.8) 0.4 (0.1–1.5) 0.4 (0.2–0.9) 0.5 (0.2–1.00) 0.4 (0.1–1.1) 0.4 (0.2–0.8)
Education
Primary or better 1 11111 1
Illiterate 2.3 (0.8–6.5) 1.6 (1.02–2.6) 2.1 (0.98–4.5) 1.5 (0.96–2.5) 1.7 (1.01–2.7) 1.6 (0.8–3.2) 1.7 (1.1–2.5)
Chewing habit
N o 1 11111 1
Yes 0.9 (0.5–1.9) 1.4 (0.9–2.0) 1.5 (0.8–2.6) 1.2 (0.8–1.8) 1.6 (1.06–2.3) 0.8 (0.5–1.4) 1.3 (0.1–1.8)
Husband’s extramarital relationships
N o 1 11111 1
Yes/uncertain 1.7 (0.9–3.1) 1.1 (0.6–2.1) 1.6 (0.7–3.6) 1.3 (0.8–2.1) 1.4 (0.8–2.5) 1.1 (0.6–2.3) 1.3 (0.8–2.1)
Anti-herpes simplex-2 antibodies
N o 1 11111 1
Yes 1.1 (0.7–1.9) 1.8 (1.2–2.6) 1.2 (0.7–2.1) 1.6 (1.1–2.3) 1.3 (0.9–1.9) 2.1 (1.2–3.5) 1.5 (1.1–2.1)
HPV¼human papillomavirus.
aDerived from a multiple logistic regression equation that included all the factors listed in the tables.
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Combinations of human papillomavirus (HPV) types in 82 women
with multiple infections in Ibadan, Nigeria are listed in Table 5.
Table 5 Combinations of human papillomavirus (HPV) types in 82
women
HPV type No HPV type No HPV type No
6,11,39 1
a 18,42,52,81,83 1
a 39,58 1
6,18,42 1
a 18,55 1 40,42 1
6,35 1
a 18,72 1 40,52 1
6,35,40,56,73 1 18,73 1 40,70 1
6,43 1
a 18,81 1 42,43 1
6,66 1
a 26,51,56 1 42,45,56,58 1
11,18,58 1 31,35,43,52 1 42,55 1
11,31 34,42 1 31,35,52,81 1 42,56 1
11,35,66,81 1 31,35,70 1 42,59 1
16,26,58 1 31,39,82 1 42,72 1
16,31,35,51,56 1
a 31,42 1 42,73 1
16,31,35,52,58,70,81 1 31,42,72,81 1 42,81 1
16,31,51 1 31,42,81,83 1 43,56,81 1
16,40,54,58,66 1 31,56,58 1 45,52,81 1
16,42,72 1 31,59 1 45,53 1
16,42,83 1
a 31,81 1 45,81 1
16,45 1 31,81,CP6108 1 51,52,56 1
a
16,52 1 33,45 2 51,66 1
a
16,52,54,66 1 33,52 1 52,72 1
16,52,55 1 33,56 1 56,58 1
16,58,66,70,83 13 5 ,42 2* 56,81 1
16,66 1
a 35,42,56,58 1 56,83 1
16,83 1 35,45 1 58,72 1
18,31 1 35,51 1 58,81 1
a
18,31,42 1 35,66 1 68,81 1
18,35,51 1
a 35,73 1 70,83 1
18,35,56,68 1 39,45 1
High-risk types in bold face.
aOne women with abnormal cervical findings.
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